AstraZeneca says detained China head has lawyer
AstraZeneca chief says group takes China probe ‘very seriously’
AstraZeneca chief executive Pascal Soriot said the company took the detention of its China president “very seriously”, as the drugmaker raised its guidance for a second straight quarter on the back of strong sales of cancer medicines.
AstraZeneca Plc is increasingly looking to the US for growth as its once fast-expanding China business faces challenges amid ...
AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...
AstraZeneca Plc (NASDAQ:AZN) reported third-quarter sales of $13.57 billion, up 18% year over year (+21% at constant currency ...
AstraZeneca said on Wednesday its China president Leon Wang had been detained by Chinese authorities and, although it did not ...
AstraZeneca PLC aims for $80 billion revenue by 2030 through strong growth in oncology, biopharmaceuticals, and rare diseases ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Drugmaker AstraZeneca lifted its annual sales and profit forecast for the second time this year on Tuesday, helped by strong ...
AstraZeneca boss Pascal Soriot (pictured)) threw his weight behind its Chinese business despite the recent arrest of its boss ...
Leon Wang, executive vice president in charge of China and the broader Asian region, is being detained while the Chinese ...
AstraZeneca Plc isn’t the only health-care company facing compliance questions in China as concern continued to swirl ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback